prostate-specific antigen RNA-pulsed dendritic cell vaccine

The prostate-specific antigen (PSA) RNA-pulsed dendritic cell (DC) vaccine is an autologous cellular immunotherapy designed to treat prostate cancer. The therapy involves isolating a patient's own dendritic cells and loading them with messenger RNA encoding the tumor-associated antigen PSA, typically via electroporation or co-incubation. These modified DCs are then reintroduced into the patient to stimulate a robust T-cell–mediated immune response specifically targeting PSA-expressing prostate cancer cells. This approach aims to overcome immune tolerance and induce cytotoxic T lymphocyte activity against tumor cells. Clinical studies have demonstrated that this strategy can reliably induce PSA-specific T-cell responses in patients with metastatic or recurrent prostate cancer, with evidence of decreased serum PSA levels and transient clearance of circulating tumor cells in some cases[1][4]. The method is considered safe and feasible for clinical use[4].

Other names

PSA RNA-loaded dendritic cell vaccinePSA mRNA-transfected DC vaccinePSA RNA-DC vaccine